Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Sponsor refiled this as active, not recruiting (was completed)
    • Trial completed
    • Primary completion date: May 8, 2026 to Jul 17, 2026
    • Study completion date: May 8, 2026 to Oct 31, 2026
  2. Trial status: Recruiting to Completed Show 4 more changesShow less
    • Primary and study completion dates changed from estimate of May 15, 2026 to May 8, 2026
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 3 of 3 entries
    • Site details revised
  3. Secondary endpoints: details revised at 3 of 3 entriesv2
  4. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 1, single-center, double-blind, placebo-controlled, dose-escalation study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM1812 following single and multiple SC administrations in normal to overweight or obese but otherwise healthy subjects.
Trial Details
NCT Number NCT07224399
Lead Sponsor BrightGene Bio-Medical Technology Co., Ltd.
Conditions
(from sponsor)		 Healhty, Overweight or Obesity
Related terms Obesity, Overweight
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov